SCHEMBL2884113

SCHEMBL2884113

NC(=O)c1ccc(Nc2nc(-c3cccc4c3oc3ccccc34)cc3ccnn23)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.37
POLB P06746 1/20 0.37
CDK2 P24941 2/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 2/20 0.36
MAPK8 P45983 2/20 0.35
MAPK10 P53779 1/20 0.35
HPGD P15428 2/20 0.35
NPC1 O15118 1/20 0.35
USP2 O75604 1/20 0.35
TSHR P16473 1/20 0.35
RAB9A P51151 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
LRRK2 Q5S007 1/20 0.35
ALOX5 P09917 3/20 0.34
PRKDC P78527 2/20 0.34
GSK3B P49841 2/20 0.34
CDK4 P11802 1/20 0.34
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2876559 0.92 TGFBR1 (0.38) NPC1RAB9AALOX5PIK3CDPIK3CB
SCHEMBL2214233 0.88 DNMT1 (0.42) SMN1; SMN2POLBMAPTKDM4EHPGD
SCHEMBL2884117 0.88 CDK2 (0.36) SMN1; SMN2POLBCDK2MAPTKDM4E
Hydrochloric Acid SCHEMBL2215243 0.88 HSD17B10 (0.38) SMN1; SMN2POLBCDK2MAPTKDM4E
SCHEMBL2216183 0.88 ALDH1A1 (0.42) SMN1; SMN2POLBMAPTKDM4EHPGD
SCHEMBL2214178 0.87 KDM4E (0.39) SMN1; SMN2MAPTKDM4EHPGDNPC1
SCHEMBL2215221 0.86 MAPT (0.42) SMN1; SMN2POLBMAPTKDM4EMAPK10
SCHEMBL2215080 0.86 LMNA (0.50) SMN1; SMN2POLBMAPTKDM4EHPGD
SCHEMBL2212315 0.86 MAPT (0.41) SMN1; SMN2MAPTKDM4EHPGDNPC1
SCHEMBL2215529 0.85 ALDH1A1 (0.38) SMN1; SMN2POLBMAPTKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 SMN1; SMN2 1421/4885POLB 828/4885CDK2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.